|View printer-friendly version|
Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
“Cidara made major progress in the third quarter and achieved significant clinical and corporate milestones. We enrolled the first patient in our Phase 2 STRIVE study of CD101 IV in candidemia, announced CD201 as the first development candidate from our proprietary Cloudbreak immunotherapy platform, and, most recently, we strengthened our balance sheet through a debt facility and a follow-on offering,” said
Third Quarter 2016 and Subsequent Highlights
- Completed Follow-on Public Offering and Secured Debt Facility: In October, Cidara successfully completed a follow-on public offering of 2,752,637 shares of common stock, including the shares issued upon the partial exercise of the underwriters’ option to purchase additional shares, at a price to the public of
$10.10per share. Proceeds from the offering were $27.8 million, before deducting underwriting discounts, commissions and offering expenses. Also in October, the company borrowed $10.0 millionunder a debt facility from Square 1 Bank, a division of Pacific Western Bank. The company may borrow up to an additional $10.0 millionunder the debt facility, subject to the achievement of certain milestones.
- First Development Candidate Selected from CloudbreakTM Immunotherapy Discovery Platform: Cidara selected the first development candidate from its proprietary immunotherapy discovery platform, Cloudbreak. Cloudbreak is the first platform of its kind designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral microbial pathogens. The selected candidate, CD201, is a novel, bispecific antimicrobial immunotherapy being developed for the treatment of multi-drug resistant bacterial infections, including those caused by MCR-1 resistant pathogens.
- Dosed First Patient in Phase 2 Trial of CD101 IV in Candidemia: Cidara initiated its Phase 2 clinical trial of CD101 IV in candidemia, the STRIVE study. STRIVE is a double-blind study comparing the safety and efficacy of CD101 IV to standard-of-care therapy, caspofungin, with an optional step-down to oral fluconazole.
Third Quarter 2016 Financial Results
- Cash, cash equivalents and short-term investments totaled
$79.3 millionas of September 30, 2016. This figure does not include any of the proceeds raised in Cidara’s October follow-on offering or from its debt facility. At December 31, 2015, cash, cash equivalents and short-term investments totaled $107.5 million.
- Research and development expenses were
$8.7 millionand $24.4 millionfor the three and nine months ended September 30, 2016, respectively, compared to $6.8 millionand $15.9 millionfor the same periods in 2015. The increases were primarily attributable to clinical development activities for our two product candidates, CD101 IV and CD101 topical, as well as preclinical development activities for our Cloudbreak platform.
- General and administrative expenses were
$3.6 millionand $9.7 millionfor the three and nine months ended September 30, 2016, respectively, compared to $2.4 millionand $6.5 millionfor the same periods in 2015. The increase resulted primarily from personnel-related costs to support the growth of our operating activities in addition to costs to operate as a public company.
- Net loss for the three months ended
September 30, 2016was $12.2 million, compared to a net loss of $9.2 millionfor the third quarter of 2015. For the nine months ended September 30, 2016and 2015, the company reported a net loss of $33.8 millionand $22.3 million, respectively.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of invasive fungal infections. CD101 topical is the first and only agent of its class being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV and CD101 topical, their potential to treat infections and the timing of the completion of the STRIVE and RADIANT Phase 2 studies, as well as the potential for CD201 to successfully treat bacterial infections and complete IND-enabling studies, and the potential for the Cloudbreak program to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
|Cidara Therapeutics, Inc.|
|Condensed Consolidated Balance Sheets|
|September 30, 2016||December 31, 2015|
|Cash, cash equivalents, and short-term investments||$||79,309||$||107,514|
|Other current assets||1,270||704|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Total liabilities and stockholders' equity||$||82,232||$||109,974|
|Cidara Therapeutics, Inc.|
|Condensed Consolidated Statements of Operations|
|Three Months Ended
|Nine Months Ended
|(In thousands, except share and per share data)||2016||2015||2016||2015|
|Research and development||$||8,729||$||6,766||$||24,389||$||15,911|
|General and administrative||3,607||2,441||9,694||6,474|
|Total operating expenses||12,336||9,207||34,083||22,385|
|Loss from operations||(12,336||)||(9,207||)||(34,083||)||(22,385||)|
|Other income (expense):|
|Interest income (expense), net||109||33||312||60|
|Total other income (expense)||109||33||312||60|
|Basic and diluted net loss per share||$||(0.88||)||$||(0.67||)||$||(2.44||)||$||(2.59||)|
|Shares used to compute basic and diluted net loss per share||13,910,145||13,674,568||13,863,453||8,636,087|
Robert H. Uhl Westwicke Partners, LLCManaging Director (858) 356-5932 firstname.lastname@example.org MEDIA CONTACT: Mike Beyer Sam Brown Inc.(312) 961-2502 email@example.com